Want to see SE:SANION full AI Analyst Report?
SANION Stock Chart & Stats
kr21.10
-kr0.15(-2.06%)
At close: 4:00 PM EST
kr21.10
-kr0.15(-2.06%)
Day’s Range― - ―
52-Week Rangekr8.03 - kr28.30
Previous CloseN/A
Volume191.43K
Average Volume (3M)1.06M
Market Cap
kr1.80B
Enterprise Valuekr1.24B
Total Cash (Recent Filing)kr531.98M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)8.1
Beta0.07
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.59
Shares Outstanding138,030,140
10 Day Avg. Volume913,988
30 Day Avg. Volume1,064,614
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr11.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt and a sizable equity base give the company durable financial flexibility over the next 2–6 months. This reduces refinancing risk, supports sustained R&D and clinical spending, and makes the firm a more attractive partner or acquirer in biotech collaborations.
Cash Generation QualityPositive operating and free cash flow that materially cover earnings indicates earnings are backed by cash rather than accounting items. This supports ongoing drug development funding, lowers immediate dilution risk, and improves the company’s ability to execute programs without urgent external financing.
High Profitability MarginsVery high TTM margins point to strong operating leverage and efficient cost structure once revenue is realized. Sustained margins enable reinvestment in trials and business development, bolster cash conversion, and provide cushion versus industry peers when revenues are steady.
Bears Say
Revenue VolatilityA pronounced decline in TTM revenue following a one-time 2024 surge undermines top-line predictability. For a clinical-stage biotech, lumpy revenue timing complicates budgeting for multi-year trials, partner negotiations and capital planning, reducing confidence in sustained growth.
Historical Capital InstabilityPrior episodes of negative equity and heavy leverage reveal that the company has previously needed aggressive financing or restructuring. That history signals a risk it may re-lever or dilute shareholders again if cash generation weakens, harming long-term capital stability.
Weak FCF Growth TrendAlthough current FCF is positive, negative FCF growth and recent multi-year cash burn indicate cash generation may be inconsistent across cycles. This can constrain multiyear R&D programs, increase the likelihood of future financing needs, and pressure strategic flexibility.
Saniona AB News
SANION FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was kr8.03 and its highest was kr28.30 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is kr1.80B.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is Aug 27, 2026 which is in 36 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on May 26, 2026. The company reported -kr0.334 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.334.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of -kr0.334 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.884%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in SE:SANION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Cantargia AB
―